DynamX Bioadaptor RCT Two-Year Outcomes: Significant Advantages vs DES

Published: 15 August 2024

  • Views:

    Views Icon 659

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Recorded at EuroPCR 2024 in Paris, these interviews provide insight into the Bioadaptor RCT trial.

These interviews are supported by

Learning Objectives

  • Understand the clinical design and goal of the Bioadaptor RCT study
  • Review the clinical endpoints and results of the study at two-year follow-up
  • Discover the clinical practice implications of the study

Target Audience

  • Interventional Cardiologists
  • PCI Operators

More from this programme

Part 1

Perspective on DynamX Bioadaptor RCT Two-Year Outcomes

In this insightful interview, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, SA) is delving into the two-year findings of the Bioadaptor RCT trial, recently presented at the EuroPCR Conference in May 2024.1 This interview will provide a comprehensive review of the trial and findings, highlighting the potential implication for the current clinical practice.

Dr Alasnag will examine the design, methodology and outcomes, offering an in-depth interpretation of the results. Additionally, Dr Alasnag will explore the clinical implications of these findings to discuss the next steps and potential impact on the future of PCI in light of the trial findings.

References:
1. Bioadaptor RCT 2 year outcomes. S. Saito. EuroPCR 2024.
1 session
Perspective on DynamX Bioadaptor RCT Two-Year Outcomes Watch now

Part 2

Summary of Outcomes of Bioadaptor RCT Two-Year

Dr Saito, the primary investigator of Bioadaptor RCT, shares a quick summary of the two-year outcomes presented at EuroPCR 2024. EuroPCR 2024 recognised the two-year Bioadaptor RCT results as one of the top three trial updates. Dr Saito highlights how the novel design and mechanism of action of DynamX Bioadaptor restores haemodynamic modulation to the artery, delivers sustained significant clinical benefit, establishing a new therapy and potentially a new standard of treatment for patients with CAD.1

References:
1. Bioadaptor RCT 2 year outcomes. S. Saito. EuroPCR 2024.
2 sessions
Summary of Outcomes of Bioadaptor RCT Two-Year Watch now
Summary of Outcomes of Bioadaptor RCT Two-Year (Japanese) Watch now

Faculty Biographies

Mirvat Alasnag

Mirvat Alasnag

Director of Catheterization Laboratory

Dr Mirvat Alasnag is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3), joining the board in October 2020 and is also on the editorial board for US Cardiology Review (USC).

Dr Mirvat Alasnag is the Director of the Catheterization Laboratory at the King Fahad Armed Forces Hospital in Jeddah, Saudi Arabia. She was the first female interventional cardiologist in the Gulf region and has since represented women on multiple medical committees, including the Saudi Arabian Cardiac Interventional Society Board & the EAPCI Women’s Steering Committee. She is the current ACCWIC International Working Group Chair and an SCAI WIN member.

Dr Alasnag trained in Clinical Cardiology and Interventional Cardiology at Loma Linda University Medical Center (Loma Linda, California) and Harper University Hospital, Detroit Medical Center (Detroit, Michigan), respectively. Since her graduation in 2009 to date, she has been…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.